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In modern cancer therapy the lack of efficiency and target speci-
ficity of anticancer drugs that cause grave side-effects are very
serious problems (Brown et al, 1981; Hellstrom et al, 1985).
Therefore, the use of drug delivery systems, for instance immuno-
conjugates composed of monoclonal antibodies against a tumour-
associated antigen and anticancer drugs, are presently being
studied by many investigators (Rowland, 1987; Kitamura et al,
1992; Reiter et al, 1994). However, despite high expectations, only
a small number of successful clinical studies on immunoconju-
gates have been reported (Takahashi et al, 1990; Pai et al, 1996).
The reasons immunoconjugates have insufficient anti-tumour
effects are: (i) poor vascular permeability in tumour tissue (an anti-
body of molecular weight 150 kDa cannot access the tumour cells
immediately) and (ii) the heterogeneity of tumour cells (a common
antibody applicable to a wide range of tumour types does not
exist) (Epenetos et al, 1986; Dvorak et al, 1991; Kennel et al,
1991; Juweid et al, 1992). A solution to these problems would be
to attack the endothelial cells lining the tumour vasculature, rather
than the tumour cells themselves. Generally, the tumour vascula-
ture that is constructed in tumour tissues by angiogenesis or
neovascularization as the tumour develops is reported to share
many common properties in various tumour types, properties that
differ from those of the normal vasculature among various tumour
types, such as enhanced permeability (Heuser et al, 1986; Dvorak
et al, 1988), suppressed leucocyte adhesion (Wu et al, 1992;
Melder et al, 1996) and high sensitivity to tumour necrosis factor a
(TNF-a) (Manda et al, 1987; Watanabe et al, 1995). These
anatomical, morphological and behavioural differences between
blood vessels in tumour tissue and in normal tissue suggest that
antigenic differences would be induced on endothelial cells by
tumour microenvironment. Recent reports indicate a higher
expression of some molecules on tumour vascular endothelium
than on normal endothelium. These molecules include, for
example, endoglin (Thorpe et al, 1995), endosialin (Rettig et al,
1992) and avb3 integlin (Brooks et al, 1994), and are considered to
be suitable targets for cancer missile therapy, since the antibody
can freely access the target without concern for vascular perme-
ability. Furthermore, killing the tumour vascular endothelium can
cause irreversible clotting, resulting in the formation of an occlu-
sive thrombus that would halt blood flow. This will cause effective
tumour regression. But the tumour vascular antigens previously
reported have also been observed to be expressed in normal
tissues. Up to now only a few studies have been reported
concerning the isolation and culture of tumour vascular endothe-
lium, so the search for molecules expressed specifically on tumour
vascular endothelium was extremely difficult. We recently estab-
lished a method for isolating tumour vascular endothelial cells
(TECs) from KMT-17 rat fibrosarcoma (Utoguchi et al, 1995a).
TECs will make it possible to discover new antigens specific
to tumour vascular endothelium. We produced a monoclonal
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Correspondence to: T Mayumiantibody (TES-23) that recognizes TECs by means of actively
immunizing mice with membranes of TECs after passive immu-
nization with endothelial cells derived from normal tissue
(Ohizumi et al, 1997). This study was conducted to assess the
distribution of the antigen recognized by TES-23 in many tumour
types in mice, rats and humans, and suggests the usefulness of
TES-23 for a targeting therapy against tumour vasculature.
MATERIALS AND METHODS
Isolation of tumour endothelial cells
TECs, or capillary endothelial cells in tumour tissue, were isolated
from KMT-17 rat fibrosarcoma (kindly donated by Dr N Takeichi,
Hokkaido University, Japan) by means of density-gradient centrifu-
gation and attach-speed separation techniques as we previously
reported (Utoguchi et al, 1995a). Briefly, minced and collagenase-
digested KMT-17 tumour tissue was separated by Percoll
(Amersham Pharmacia Biotech, Sweden) density-gradient centrifu-
gation. The cells in the fraction enriched with endothelial cells were
plated on tissue culture dishes in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf serum (FCS)
and 50 mg ml–1 of endothelial cell growth supplement (ECGS,
Sigma Chemical Co., St Louis, MO, USA). After 24 h of culture,
the non-adhesive cells were washed out with Hank’s buffered salt
solution; the remaining TECs were cultured and used within
passage 2. As endothelial cells of normal tissue, capillary endo-
thelial cells in the epididymal fat pad (FCECs) were isolated from
male WKAH rats using collagenase-digestion and Percoll density
gradient separation, described by Madri et al (1983).
Preparation of antibodies
In order to obtain a tumour endothelial cell-specific antibody,
we followed procedures as we previously described (Ohizumi
et al, 1998). The outside-out membrane vesicles from plasma
membrane of TECs or FCECs were prepared by treatment with
100 mM paraformaldehyde, 2 mM dithiothreitol, 1 mM calcium
chloride and 0.5 mM magnesium chloride in DMEM at 37°C
overnight (Scott, 1976). Passive immunization of the membrane
fraction of FCECs was carried out, followed by active immuniza-
tion of TECs to BALB/c mice. Hybridomas were constructed with
spleen cells of the immunized mice and P3X63Ag8U.1 myeloma
cells (ATCC CRL-1597). Screening of hybridoma-secreted anti-
bodies that did not recognize FCECs, but did recognize TECs, was
conducted by cell-ELISA (enzyme-linked immunosorbent assay)
and by an immunostaining analysis of WKAH rats bearing
KMT-17 fibrosarcomas. One hybridoma-produced antibody that
recognized TECs in cell-ELISA and endothelium in KMT-17
fibrosarcoma, but not FCECs and a normal tissue, was selected.
The antibody, named TES-23, was an IgG1 isotype. MOPC, the
antibody produced by the MOPC-31C hybridoma (ATCC CCL-
130) whose isotype was also IgG1, was used as the negative
control.
Immunostaining of tissue sections of KMT-17
fibrosarcoma
Tumour tissue and normal tissue were embedded in O.C.T.
Compound (Miles, Elkhart, IN, USA) and frozen in liquid nitrogen.
Sections (5 mm) were prepared and fixed with acetone. Endogenous
peroxidase was blocked by treatment with 0.3% hydrogen peroxide
in methanol. After blocking with horse serum, the tissue sections
were treated with TES-23, followed by biotinylated horse anti-
mouse IgG. After incubation with horseradish peroxidase–strepta-
vidin conjugate (Vector, Burlingame, CA, USA) for 30 min at room
temperature, the tissue sections were stained with 0.125 mg ml–1 of
3,3¢-diaminobenzidine in 50 mM Tris-HCl (pH 7.2) and 0.01%
hydrogen peroxide. They were counterstained with haematoxylin
and eosin for microscopic analysis.
125I labelling of antibodies
TES-23 and MOPC were radiolabelled with 125I by the IodoGen
method described below. Briefly, 18 ml of 0.4-M phosphate buffer
(pH 7.5), 2 ml of antibody solution (0.5 mg ml–1 in phosphate-
buffered saline (PBS)) and 2 ml of sodium 125I iodide (DuPont,
Boston, MA, USA) were mixed in IodoGen (Pierce Chemical Co.,
Rockford, IL, USA) coated glass vials and reacted for 5 min at
room temperature. The reaction mixture was removed from the
vial and desalted on an EconoPac 10DG column (Bio Rad
Laboratories, Hercules, CA, USA) equilibrated with PBS
containing 0.2% bovine serum albumin and 5 mg ml–1 of potas-
sium iodide. The desalting process was repeated two times and the
final product was used for the experiments. The specific radio-
activities of both 125I-labelled TES-23 and 125I-labelled MOPC
were 1.0 ´ 1010 cpm mg–1 of protein.
Estimation of tissue distribution of TES-23
WKAH/Hkm rats (females, 4 weeks old) and BALB/c mice
(females, 4 weeks old) and BALB/c-nu Slc (females, 6 weeks old)
were purchased from Japan SLC, Inc. (Shizuoka, Japan) and main-
tained under specific pathogen-free conditions at our animal facility.
All experimental protocols with animals in this study complied with
the institutional ‘Guide for the Care and Use for Laboratory
Animals’. KMT-17 fibrosarcomas were maintained in solid form in
WKAH rats. Tumour tissue was removed aseptically and passed
through stainless steel mesh to produce single cells. A total of
1 ´ 106 KMT-17 cells were inoculated subcutaneously into the
abdomen of WKAH rats. Meth-A fibrosarcomas were maintained
as ascites in BALB/c mice. A total of 5 ´ 105 Meth-A cells were
inoculated subcutaneously (s.c.) in the abdomen of BALB/c mice.
Colon-26 adenocarcinomas were maintained in solid form in
BALB/c mice. Single cells were prepared from tumour tissue and
5 ´ 105 cells were inoculated s.c. into the abdomen of BALB/c
mice. HT-1080 human-derived fibrosarcoma was grown in Eagle’s
modified essential medium (EMEM) with 10% FCS and a non-
essential amino acid mixture. A total of 5 ´ 106 HT-1080 cells
were inoculated s.c. into the abdomen of nude mice. These animals
were used for the experiments 1 week after inoculation of cells,
when the tumour diameter reached 6–8 mm. Radiolabelled anti-
bodies (100 ng for rats or 20 ng for mice) were injected intra-
venously (i.v.). One hour later, the animals were deeply
anaesthetized by pentobarbital sodium and were dehaematized via
the abdominal aorta and each organ was removed and radioactivity
was counted by auto gamma counter (Packard Instrument Co. Inc.,
Meriden, CT, USA). In competitive experiments in Meth-A-
bearing mice, 2 mg of unlabelled antibodies were administered i.v.
30 min before injection of 125I-labelled TES-23.
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Human tissue samples were provided by Dr H Shiozaki (Osaka
University, Japan), and Dr K Nakahara (Ohtemae Hospital, Osaka,
Japan); all had been donated by cancer patients under informed
consent. Tumour tissue and surrounding normal tissue were used
for immunostaining as described above.
Immunoconjugates
Neocarzinostatin (NCS) was chemically conjugated to TES-23 or
MOPC by the method using the cross-linkers, 3-(2-pyridyl-
dithio)propionyl hydrazide (PDPH) and 2-iminothiolane (IT), which
was described by Friden et al (1993). This reaction formed disulphide
bonds between the carbohydrate chains of the Fc region of the anti-
bodies and the amino residues of NCS. The immunoconjugates,
TES-23-NCS and MOPC-NCS, were purified by gel filtration chro-
matography. Both conjugates were estimated to include two NCS
molecules per antibody. The immunoconjugates or NCS were admin-
istered i.v. to WKAH rats bearing KMT-17 tumours on days 7, 10
and 13 after tumour inoculation. Tumour volume was calculated
from the formula described by Haranaka et al (1984).
Statistical analysis
Tissue distribution and tumour volume were statistically evaluated
by Student’s t-test.
RESULTS
Tumour vascular localization of the antigen recognized
by TES-23
Since TES-23 was produced by immunizing with TECs isolated from
KMT-17 fibrosarcoma, we first performed an immunohistochemical
study in tissue sections of KMT-17. TES-23 stained the vascular
endothelium in tumour tissue, but did not stain tumour cells or
stromal cells (Figure 1A). On the other hand, no stained area was
observed with MOPC, a negative control antibody from MOPC-31C
hybridoma (Figure 1B). In the sections of normal kidney, endothelial
Tumour vascular targeting with TES-23 antibody 1157
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Figure 1 Immunostaining of KMT-17 rat fibrosarcoma with TES-23. Indirect immunostaining was carried out on tissue sections of KMT-17 fibrosarcoma.
TES-23 (A), or negative control antibody (B), was used for the first antibody
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Figure 2 Tissue distribution of 125I-labelled TES-23 in WKAH rats bearing
KMT-17 fibrosarcomas. 100 ng (1 ´ 106 cpm 400 ml–1 head–1) of radiolabelled
TES-23 (solid bars) or MOPC (open bars) were injected intravenously into
tumour-bearing rats. One hour later the rats were anaesthetized and
dehaematized via the abdominal aorta. Each organ was removed and its
radioactivity was counted by an auto gamma counter. Data are represented
as % of injected dose g–1 of wet tissue. Each value shown is the mean ± s.d.
for four animals. Statistical significance compared with MOPC treated group:
*P < 0.01cells were not stained. In liver sections, weak staining was observed
on the arterioles endothelium (data not shown).
Tissue distribution of TES-23 in rats bearing KMT-17
To evaluate in detail the distribution of antigens recognized by
TES-23 in vivo, 125I-labelled TES-23 was injected i.v. and the
radioactivity of each organ was counted 1 h after injection.
Because TES-23 was considered to bind to antigen on the endothe-
lium inside blood vessels, short-term accumulation was tested. As
shown in Figure 2, 19% of the injected dose of TES-23 accumu-
lates in the tumour per gram of tissue, a percentage, that was 25
times higher than that of MOPC. Other organs showed no obvious
accumulation, except for the spleen.
Tissue distribution of TES-23 in tumour-bearing mice
Rat KMT-17 fibrosarcoma was the parent tumour tissue from
which TECs were isolated. The properties seen in tumour vascular
endothelium were usually common to all species of animals exam-
ined and to many tumour types. Because tumour vascular antigens
were presumed to exist in mice, the tissue distribution of TES-23
was studied in mice bearing Meth-A or Colon-26 tumours. In
Meth-A-bearing BALB/c mice, TES-23 dramatically accumulated
in tumour tissue: it was 50 times higher than MOPC accumulation
1 h after injection (Figure 3A). In mice bearing Colon-26 adeno-
carcinomas, a large accumulation of TES-23 in tumour tissue was
also observed (Figure 3B). No obvious radioactivity was observed
in any normal organs of these tumour-bearing mice. Furthermore,
preadministration of a 100-molar excess of unlabelled TES-23
competitively blocked the accumulation of 125I-labelled TES-23 to
the Meth-A tumour (Figure 3C). No changes in tumour accumula-
tion were observed when MOPC was given before 125I-labelled
TES-23 was administered.
Tissue distribution of TES-23 in nude mice bearing a
human tumour cell line
HT-1080, a human fibrosarcoma cell line, was also used for the
tissue distribution study. BALB/c nude mice with HT-1080 were
given TES-23 i.v., and the accumulation of TES-23 in tumour
tissue was examined. Figure 4 shows the tumour-specific accumu-
lation of TES-23 in human sarcoma, which amounted to 82% of
the injected dose per gram of tissue compared with 3.2% for
MOPC.
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Figure 3 Tissue distribution of 125I-labelled TES-23 in tumour-bearing mice. Tissue distribution experiments were performed in BALB/c mice bearing Meth-A
fibrosarcomas (A) or Colon-26 adenocarcinomas (B). A total of 20 ng (2 ´ 105 cpm 200 ml–1 head–1) of radiolabelled antibodies were injected intravenously into
mice. One hour later the mice were anaesthetized and dehaematized via the abdominal aorta. Each organ was removed and its radioactivity was counted by an
auto gamma counter. Data are represented as % of injected dose g–1 of wet tissue. (C) Unlabelled TES-23 or MOPC (2 mg head–1) was administered 30 min
before injection of 125I-labelled TES-23 in Meth-A-bearing mice. Data are represented as % of injected dose g–1 of wet tissue. Each value shown is the mean ±
s.d. for five animals. Statistical significance compared with MOPC treated group (A,B): *P < 0.01
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Figure 4 Tissue distribution of 125I-labelled TES-23 in nude mice bearing a
human tumour cell line. HT-1080 human fibrosarcoma cells were inoculated
subcutaneously to BALB/c-nu mice. A total of 20 ng (2 ´ 105 cpm 200 ml–1
head–1) of radiolabelled antibodies were injected intravenously into mice. One
hour later the mice were anaesthetized and dehaematized via the abdominal
aorta. Each organ was removed and its radioactivity was counted by an auto
gamma counter. Data are represented as % of injected dose g–1 of wet
tissue. Each value shown is the mean ± s.d. for five animals. Statistical
significance compared with MOPC treated group: *P < 0.01Immunostaining of sections of human cancer tissue
To clarify whether or not the tumour vascular antigen recognized
by TES-23 was expressed on human cancer tissue, oesophagus
cancer sections were prepared for immunostaining. Endothelium
stained by an antibody to factor VIII, an endothelial marker, was
similarly stained with TES-23 in the cancer tissue (Figure 5C). The
cross-reactivity of TES-23 in other types of cancers was investi-
gated in specimens of oesophagus, stomach, colon and breast
cancer tissue. The endothelium in one of two oesophagus cancer
specimens was positively stained, as well as in one of two stomach
cancer specimens, two of two colon cancer specimens, and two of
two breast cancer specimens. In contrast, normal tissues around
the cancer were weakly stained with TES-23 in two stomach tissue
specimens and the other five normal tissue specimens, including
two oesophagus, two colon and one breast tissue specimens, were
all negative (data not shown).
Tumour vascular targeting with immunoconjugate in
vivo
Immunoconjugate composed of TES-23 and neocarzinostatin
(NCS), an anti-cancer drug, was synthesized in order to confirm
the effectiveness of tumour vascular targeting by TES-23 in vivo.
Rats bearing KMT-17 tumours, which were 7–8 mm in diameter,
were injected i.v. with TES-23-NCS or other samples. In rats with
TES-23-NCS injection, tumour growth was dramatically inhibited
with a dosage of 17 mg kg–1 of NCS, and haemorrhagic necrosis
(which was like TNF-a induced tumour necrosis) was observed in
the tumours (data not shown). Although growth inhibition of
tumours was seen in the group injected with NCS (500 mg kg–1),
two of the five rats died before day 13 and the others lost much of
their body weight. On the other hand, TES-23-NCS caused little
decrease in body weight. No obvious anti-tumour effects were
seen with MOPC-NCS, a negative control. In addition, unconju-
gated TES-23, in a dose of 107 mg kg–1, did not show an anti-
tumour effect, but a higher dose (10 mg kg–1) caused growth
inhibition of tumours (Ohizumi et al, 1997).
DISCUSSION
In this study, we attempted to indicate the usefulness of the TES-
23 antibody for tumour vascular targeting and the existence of
antigens on endothelium distributed among a wide variety of
tumour cell types. Previously, the search for molecules specific to
tumour vasculature was not easy because the isolation or cultiva-
tion of tumour vascular endothelial cells was difficult. We and
another group recently reported ways for isolating endothelial cells
derived from tumour tissue in animals (Modzelewski et al, 1994;
Utoguchi et al, 1995). This work makes possible attempts to deter-
mine specific antigens on tumour vascular endothelium. As we
previously reported, in order to obtain a monoclonal antibody
recognizing TECs but not normal endothelial cells, we performed
an active immunization in mice of plasma-membranes from TECs
isolated from rat KMT-17 fibrosarcoma, after passive immuniza-
tion with endothelial cells of normal tissue derived from
epididymal fat. TES-23 antibody from a screened hybridoma
highly reacted with TECs in vitro (Ohizumi et al, 1998).
Immunostaining of tumour tissue sections of KMT-17 fibrosar-
coma showed a specific expression of an antigen on endothelium,
which recognized by TES-23, but not on tumour cells or stromal
cells. Endothelium in liver and kidney did not stain with TES-23.
These results show that the tumour vascular endothelium
Tumour vascular targeting with TES-23 antibody 1159
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Figure 5 Immunohistochemical identification of TES-23-binding antigen on endothelium in human cancers. Serial tissue sections of oesophagus cancer were
stained with: (A) haematoxylin-eosin; (B) TES-23; (C) anti-human factor-VIII antibody; (D) control IgG1expresses an antigen recognized by TES-23 in vivo and that this
antigen is specific to tumour tissues. To clarify the systemic distri-
bution of TES-23-binding antigens, 125I-labelled TES-23 was used.
An analysis of tissue in rats bearing KMT-17 fibrosarcoma
suggested that the antigen selectively exists in tumour tissue. A
monoclonal antibody used as a conventional targeting molecule
against tumour-associated antigens expressed on tumour cells
themselves generally accumulates in the tumour only in an amount
that is several times higher than a control antibody after i.v. injec-
tion (Laborda et al, 1990; Camera et al, 1993). The large and rapid
accumulation of TES-23 seen in this study suggests that TES-23
binds to the endothelium in vivo. The spleen shows a slightly high
accumulation of TES-23 when compared with other normal
organs. In the experiments in mice, no obvious accumulation in the
spleen was observed. It is unclear whether spleen cells or splenic
endothelium of rats express the antigen recognized by TES-23 or
not. A detailed examination is now in progress.
To investigate the existence of the tumour vascular endothelial
antigen in other animal species, mice bearing Meth-A fibrosar-
comas and Colon-26 adenocarcinomas were used for tissue distri-
bution experiments. In both tumour types, TES-23 showed a rapid
accumulation in the tumour without distribution to normal tissues.
The competitive inhibition of accumulation in tumour tissues by
the preadministration of excessive unlabelled TES-23, but not
MOPC, suggested that TES-23 binds to the tumour vascular
endothelium by specific antigens. These results indicate that TES-
23-binding molecules are specifically expressed on tumour
vascular endothelial cells of various tumour types and animal
species. TES-23 also accumulated in the HT-1080 human tumour
in nude mice. Although the blood vessels induced into the tumour
tissue in this nude mouse model were of mouse origin, the result
suggests that the expression of TES-23-binding molecules would
be induced on endothelium in human tumours. We previously
reported that tumour vascular properties, such as enhanced perme-
ability and suppressed leucocyte adhesion, were reproduced by
endothelial cells derived from bovine veins of normal tissue,
cultured with conditioned medium of a tumour cell line in vitro
(Utoguchi et al, 1995b, 1996). Another group reported that leuco-
cyte adhesion to human umbilical-vein endothelial cells was
suppressed when treated with basic fibroblast growth factor, an
angiogenic factor secreted by tumour cells (Griffioen et al, 1996a,
1996b; Medler et al, 1996). Thus soluble factors secreted from
tumour cells may induce anatomical or behavioural changes in
tumour vascular endothelium.
Most interesting was the expression of TES-23-binding mole-
cules on endothelial cells in a clinical human cancer. Figure 5
reveals that the antigen would exist on endothelium in the oesoph-
agus cancer and other various cancer types (colon, stomach,
breast) that we examined (data not shown). It would be very inter-
esting to investigate the functions and the systemic distribution of
this antigen in humans. Detailed examinations are now in progress
in order to determine what the TES-23-binding molecule is. Our
preliminary experiments showed that TES-23 binds to an 80 kDa
molecule assembled with a 40-kDa molecule present on TECs in
vitro (relational data are shown by Ohizumi et al, 1998). These
antigens may be CD44, an adhesion molecule, and OTS-8, an
antigen related to differentiation (Nose et al, 1990; Harada et al,
manuscript in preparation). Moreover, the staining pattern of tissue
sections from various organs showed differences between TES-23
and a common anti-CD44 antibody. These findings have not been
reported previously; they are now being confirmed.
Recently, the antibody-based targeting therapy for solid tumours
has been recognized by many investigators in order to overcome
such clinical problems as inefficiency or side-effects of anticancer
drugs. But because these approaches are problematical, the effect
of immunoconjugates is not enough. Important issues include the
poor penetration of tumour masses by immunoconjugates and the
limited distribution of the antigen among various tumour types.
Tumour vascular targeting, proposed originally by Juliana
Denekamp (Denekamp, 1984), is considered to be a superior
approach that causes endothelial damage in tumour tissues in order
to induce clotting at the site of damage and to halt the blood flow.
Solid tumours would be killed effectively in this way. Critical
points in this approach include the lack of suitable target antigens
found on tumour vascular endothelium. Burrows et al (1993)
reported on tumour vascular targeting against MHC class II
antigen highly expressed on endothelium in tumour tissue of
C1300(Mug) cells, an interferon gamma gene transfectant tumour
cell line. In this murine model, immunoconjugates composed of
anti-MHC class II antibody and Ricin A-chain induced marked
regression of the tumour. However, this endothelial antigen does
not naturally occur in common tumours and MHC class II mole-
cules seen on normal cells, for example antigen-presenting cells.
Then we performed cancer therapy experiments with immunocon-
jugate composed of TES-23 and neocarzinostatin in rats bearing
KMT-17 fibrosarcomas. Marked anti-tumour effects were shown
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Figure 6 Effect of TES-23-NCS immunoconjugate on tumour-bearing rats.
Rats bearing KMT-17 fibrosarcomas were given TES-23-NCS (TES-23:
107 mg kg–1, NCS: 17 mg kg–1), MOPC-NCS (MOPC: 107 mg kg–1, NCS:
17 mg kg–1), NCS (500 mg kg–1) or saline by intravenous injection on days 7,
10 and 13 after tumour inoculation. Data are represented as tumour volume.
Each value shown is the mean ± s.d. for five animals. Statistical significance
compared with saline treated group: *P < 0.05only in rats given TES-23-NCS, but not MOPC-NCS, and explain
the specificity of TES-23-NCS against the tumour vascular
endothelium. It is also indicated that the effects were not a result
from the simple prolongation of half-life of NCS by the conjuga-
tion with an antibody. Preliminary experiments also show that
TES-23-NCS exhibits dramatic anti-tumour effects in mice
bearing Meth-A tumour (data not shown). Therefore TES-23 may
recognize, with high specificity, a naturally occurring antigen on
endothelial cells in various tumour types. TES-23 will become a
novel drug carrier for tumour targeting and TES-23-binding
molecule will be a new target for cancer therapy in future.
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